Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study
Open Access
- 19 June 2020
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (11) , 2055-2068
Abstract
Aims Type 2 diabetes mellitus (T2DM) is a public health threat. Men with T2DM often exhibit hypogonadism. We investigated whether testosterone therapy (TTh) in men with hypogonadism and T2DM improves glycemic control, insulin sensitivity and results in remission of T2DM. Material and Methods 356 men who had total testosterone (T) ≤12.1 nmol/L (350 ng/dL) and symptoms of hypogonadism were included in the study and observed for 11 years. All patients received standard diabetes treatment. 178 men additionally received parenteral T undecanoate 1000 mg every 12 weeks following an initial 6‐week interval. 178 hypogonadal men who opted against TTh served as control group. Results Men with hypogonadism and T2DM treated with T had significant progressive and sustained reductions in fasting glucose, HbA1c and fasting insulin over the treatment period. In the control group, fasting glucose, HbA1c and fasting insulin increased. 34.3% of men treated with T achieved remission of their diabetes and 46.6% of patients achieved normal glucose regulation. 83.1% of the T‐treated group reached HbA1c target of 6.5%, 90% achieved HbA1c target of 7.0%. In contrast, no remission of diabetes or reduction in glucose or HbA1c levels were noted in the control group. There were fewer deaths, myocardial infarctions, strokes, and diabetic complications in the T‐treated group. Conclusions Long‐term TTh in men with T2DM and hypogonadism improves glycemic control and insulin resistance. Remission of diabetes occurred in one third of the patients. TTh is potentially a novel additional therapy for men with T2DM and hypogonadism.Keywords
Funding Information
- Bayer
This publication has 47 references indexed in Scilit:
- Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetesEuropean Journal of Endocrinology, 2013
- The Incidence of Hypogonadotropic Hypogonadism in Type 2 Diabetic Men in Polish PopulationBioMed Research International, 2013
- Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male ratJournal of Lipid Research, 2013
- ErratumJNCI: Journal of the National Cancer Institute, 2012
- Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)Diabetes Care, 2011
- Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 DiabetesDiabetes Care, 2007
- Low Testosterone and High C-Reactive Protein Concentrations Predict Low Hematocrit in Type 2 DiabetesDiabetes Care, 2006
- Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetesEuropean Journal of Endocrinology, 2006
- Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2004
- Use and Abuse of HOMA ModelingDiabetes Care, 2004